Gilgamesh Pharmaceuticals Inc. has identified arylcyclo-hexylamine derivatives targeting N-methyl-D-aspartate receptor (NMDAR) and/or serotonin transporter (SERT) reported to be useful for the treatment of substance abuse and dependence, depression and mood and anxiety disorders.